Newly identified biomarkers, and evidence to support their potential pharmacogenomic (PGx) relevance, can help address challenges involved with optimizing personalized drug therapy.
In this webinar, Dr. David Kisor from Manchester University presents the latest evidence supporting newly identified (predictive) biomarkers for pharmacogenomics (PGx) as well as evaluating the relevance of certain existing biomarkers. He will introduce a new resource that will be available for comparing and contrasting Clinical Pharmacogenetic Implementation Consortium (CPIC) and U.S. Food and Drug Administration (FDA) PGx data.
- Learn how drug efficacy and safety are related to pharmacogenomic interindividual variability in pharmacokinetics and pharmacodynamics.
- Hear about pharmacogenomics education programs including an accredited PGx graduate degree and a PGx certification program for professionals.
Presented by Dr. David Kisor, Professor of Pharmaceutical Sciences and Pharmacogenomics and Director of Pharmacogenomics, Manchester University
Recorded on May 26, 2022
Learn more about our pharmacogenetics solutions.
